Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants

Experimental Gerontology

Volumn 47, Issue 5, 2012, Pages 347-352

  Bruno, Davide ^a,b   Pomara, Nunzio ^a,b   Nierenberg, Jay ^a,b   Ritchie, James C ^c   Lutz, Michael W ^d,e   Zetterberg, Henrik ^e   Blennow, Kaj ^f  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; APOE; Cerebrospinal fluid; Cortisol; Memory performance; Neurofilament light; TOMM40

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; DNA; HYDROCORTISONE; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MOLECULAR INTERACTION; ONSET AGE; PRIORITY JOURNAL; PROTECTION; PROTEIN CEREBROSPINAL FLUID LEVEL; TOMM40 GENE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROCORTISONE; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE TRANSPORT PROTEINS; MEMORY; NEUROFILAMENT PROTEINS;

EID: 84859852643     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2011.09.008     Document Type: Article

References (40)

1. Bjerke M., Andreasson U., Rolstad S., Nordlund A., Lind K., Zetterberg H., Edman A., Blennow K., Wallin A., Subcortical A. vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr. Disord. 2009, 28:348-356.
2. Blennow K. Dementia in 2010: paving the way for Alzheimer disease drug development. Nat. Rev. Neurol. 2011, 7:65-66.
3. Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
4. Blennow K., DeLeon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. Nat. Rev. Neurol. 2010, 6:131-144.
6. Bruno D., Nierenberg J.J., Ritchie J.C., Lutz M.W., Pomara N. CSF cortisol concentrations in healthy elderly are affected by both APOE and TOMM40. Psychoneuroendocrinology 2012, 37:366-371.
7. Buschke H. Retrieval in human learning. Trans. N.Y. Acad. Sci 1974, 36:721-729.
8. Caselli R.J., Saunders A.M., Lutz M.W., Huentelman M.J., Reiman E.M., Roses A.D. TOMM40, APOE, and age of onset of Alzheimer's disease. Poster session presented at the Alzheimer's Association International Conference on Alzheimer's Disease. Honolulu, HI 2010, July.
9. Constantinescu R., Zetterberg H., Holmberg B., Rosengren L. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat. Disord 2009, 15:205-212.
10. Corder E.H., Saunders A.M., Strittmater W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
11. de Jong D., Jansen R.W.M.M., Pijnenburg Y.A.L., van Geel W.J.A., Borm G.F., Kremer H.P.H. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 2007, 78:936-938.
12. Friede R.L., Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat. Rec. 1970, 167:379-387.
13. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 2008, 67:309-318.
14. Grinberg L.T., Rüb U., Ferretti R.E.L., Farfel J.M., Polichiso L., Gierga K., Jacob-Filho W., Heinsen H. The dorsal raphe nucleus shows phosphor-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathology and Applied. Neurobiology 2009, 35:406-416. Brazilian Brain Bank Study Group.
15. Gudmundsson P., Skoog I., Waern M., Blennow K., Zetterberg H., Rosengren L., Gustafson D. Is there a CSF biomarker profile related to depression in elderly women?. Psychiatry Res. 2010, 176:174-178.
16. Gunnarson M., Malmestrom C., Rosengren L., Lycke J., Svenningsson A. Reply to "The neurofilament light chain is not stable in vitro" by Koel-Simmelink et al. Ann. Neurol. 2011, 69:1066-1067.
17. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., Price D.L. Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl. Acad. Sci. 1987, 84:3472-3476.
18. Hu Y.Y., He S.S., Wang X.C., Duan Q.H., Khatoon S., Iqbal K., Grundke-Iqbal I., Wang J.Z. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 2002, 320:156-160.
19. Jones E.L., Kalaria R.N., Sharp S.I., O'Brien J.T., Francis P.T., Ballard C.G. Genetic associations of autopsy-confirmed vascular dementia subtypes. Dement. Geriatr. Cogn. Disord. 2011, 31:247-253.
20. Koel-Simmelink M.J., Teunissen C.E., Behradkia P., Blankestein M.A., Petzold A. The neurofilament light chain is not stable in vitro. Ann. Neurol. 2011, 69:1065-1066.
21. Lutz M.W., Crenshaw D.G., Saunders A.M., Roses A.D. Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Dement. 2010, 6:125-131.
22. Mesulam M., Shaw P., Mash D., Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. Neurol. 2004, 55:815-828.
23. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987:25-31.
24. Petzold A., Keir G., Warren J., Fox N., Rossor M.N. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegenerative Dis. 2007, 4:185-194.
25. Pijnenburg Y.A.L., Janssen J.C., Schoonenboom N.S.M., Petzold A., Mulder C., Stigbrand T., Norgren N., Heijst H., Hack C.E., Scheltens P., Teunissen C.E. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement. Geriatr. Cogn. Disord. 2007, 23:225-230.
26. Pomara N., Bruno D., Nierenberg J.J., Sidtis J.J., Martiniuk F.T., Mehta P.D., Zetterberg H., Blennow K. TOMM40 poly-T variants and CSF amyloid beta levels in the elderly. Neurochem. Res. 2011, 36:1124-1128.
27. Pomara, N., Bruno, D., Sarreal, A.S., Hernando, R.T., Nierenberg, J., Petkova, E., Sidtis, J.J., Wisniewski, T.M., Mehta, P.D., Pratico, D., Zetterberg, H., Blennow, K., in press. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am. J. Psychiatry.
28. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996, 67:2013-2018.
29. L.E. Rosengren, J.E. Karlsson, J.O. Karlsson, L.I. Perrson, C. Wikkelso. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. 67 (1996) 2013-2018.
30. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999, 52:1090-1093.
31. Roses A.D., Lutz M.W., Amrine-Madsen H., Saunders A.M., Crenshaw D.G., Sundseth S.S., Huentelman M.J., Welsh-Bohmer K.A., Reiman E.M. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2009, 10:375-384.
32. Rutherford A. ANOVA and ANCOVA: A GLM approach 2011, Wiley, Hoboken, NJ.
33. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000, 54:1960-1964.
34. Sjogren M., Blomberg M., Jonsson M., Wahlund L.O., Edman A., Lind K., Rosengren L., Blennow K., Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 2001, 66:510-516.
35. Teunissen C.E., Petzold A., Bennet J.L., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
36. Trojanowski J.Q., Schuck T., Schmidt M.L., Lee V.M. Distribution of tau proteins in the normal human central and peripheral nervous system. J. Histochem. Cytochem. 1989, 37:209-215.
37. van Eijk J.J.J., van Everbroeck B., Abdo W.F., Kremer B.P.H., Verbeek M.M. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J. Alzheimers Dis. 2010, 21:569-576.
38. Van Geel W.J., Rosengren L.E., Verbeek M.N. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J. Immunol. Methods 2005, 296:179-185.
39. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van der Perre B., Sjögren M., Andreasen N., Blennow K., Quantification K. of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000, 285:49-52.
40. Zetterberg H., Hietala M.A., Jonsson M., Andreasen N., Styrud E., Karlsson I., Edman A., Popa C., Rasulzada A., Blennow K., Wallin A. Neurochemical aftermath of amateur boxing. Arch. Neurol. 2006, 67:1277-1280.